HS
Therapeutic Areas
ALX Oncology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Evorpacept + Trastuzumab + Chemotherapy (ASPEN-09) | HER2+ Breast Cancer | Phase 1 |
| Evorpacept + Trastuzumab + Ramucirumab + Paclitaxel (ASPEN-06) | 2L/3L Advanced HER2+ Gastric/GEJ Adenocarcinoma | Phase 2/3 |
| Evorpacept + SARCLISA® + Dexamethasone | Relapsed/Refractory Multiple Myeloma (RRMM) | Phase 1/2 |
| Evorpacept + Zanidatamab | HER2-Expressing Breast Cancer and Other Cancers | Phase 1b/2 |
| Evorpacept + Fam-Trastuzumab Deruxtecan-Nxki (ENHERTU®) | HER2-positive Metastatic Breast Cancer | Phase 1/1b |
| ALX2004 | EGFR-Expressing Solid Tumors (NSCLC, CRC, HNSCC, ESCC) | Phase 1 |